H.C. Wainwright continues to endorse Aligos Therapeutics Inc. (NASDAQ:ALGS) with a Buy recommendation and an optimistic price target of $50. This valuation represents a considerable upside compared to the stock’s current trading price of $8.54, which InvestingPro data indicates remains below its intrinsic Fair Value.
The focal point is Aligos's ongoing Phase 2 B-SUPREME trial assessing pevifoscorvir sodium (pevy) as a treatment for chronic hepatitis B virus (HBV) infection. The study has successfully enrolled 144 patients worldwide, with predetermined interim analyses planned for the first and second halves of 2026, in line with the trial protocol.
Analysts at H.C. Wainwright anticipate that forthcoming interim data will highlight the degree of HBV DNA reduction in patients, offering a direct comparison to outcomes observed during Phase 1. They emphasize that any adjustments to sample size will adhere strictly to the protocol’s stipulations and should not be interpreted as indicative of an efficacy shortfall.
From a financial perspective, InvestingPro data shows Aligos as having a favorable current ratio of 4.7, indicating liquidity well above immediate obligations. However, the company is also characterized by a rapid cash burn rate consistent with its clinical development stage.
Management portrays pevifoscorvir primarily as a monotherapy foundation for chronic viral suppression, with additional promise for combination treatments aimed at achieving functional cures. There is also potential applicability to hepatitis delta virus (HDV) therapies. Moreover, Aligos is engaging with global regulatory bodies to align its development strategy and maintains sustained interest in its metabolic dysfunction-associated steatohepatitis (MASH) program.
These updates serve to diminish uncertainties surrounding the anticipated 2026 interim and 2027 topline data releases. The clinical progress and strategic focus reinforce Aligos’s long-term positioning within the hepatic virology and metabolic liver disease domains, bolstering prospects for significant value generation.
Investors should note that Aligos is scheduled to report its next quarterly earnings on March 9, 2026. For stakeholders seeking comprehensive analysis, InvestingPro provides additional insights and extensive financial metrics covering Aligos’s stock and its inherent volatility.
In parallel developments, Aligos has announced the appointment of James Hassard as Executive Vice President and Chief Commercial Officer, a move aimed at strengthening its commercial strategy on the global stage. This management enhancement aligns with UBS’s recent initiation of coverage on Aligos, which carries a Buy rating and spotlights the company’s robust pipeline targeting liver diseases. UBS also flagged that the stock trades below its cash value, underscoring potential undervaluation.
On the preclinical front, Aligos’s thyroid hormone receptor beta agonist, ALG-055009, has displayed encouraging results. When administered in combination with incretin receptor agonists such as semaglutide and tirzepatide, ALG-055009 generated pronounced weight loss effects in diet-induced obese mice, surpassing outcomes from either agent alone.
These advancements collectively illustrate Aligos’s commitment to developing innovative therapies across its hepatic and metabolic portfolios while enhancing its positioning in competitive biotech markets.